In line with these results, another clinical trial performed with the same butyrate concentration and intervention duration but including both males and females with MetS (n = 12) showed no effects on insulin sensitivity parameters while in this study the fecal SCFA levels remained unchanged. The gene discussed is INS; the disease is metabolic syndrome.